⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 16, 2024

Figure S7 from Targeting the immunoglobulin IGSF9 enhances anti-tumor T cell activity and sensitivity to anti-PD-1 immunotherapy

Yifan Liu Hongying Wang Xinyu Zhao Jiashen Zhang Zhiling Zhao Xia Lian Juan Zhang Feng Kong Tao Hu Ting Wang Xiaohua Li Lei Wang Dapeng Wang Chunling Li Huiwen Luan Xiaoli Liu Chunyan Wang Yun Jiang Xiaomin Li Fangmin Li Shuhao Ji Yaopeng Wang Zunling Li

View Full Paper

Ask AI

Bookmark

Share

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Abstract

Anti-IGSF9 reversed the inhibition of T cells mediated by IGSF9-ECD.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Liu et al. (2024) studied this question.

synapsesocial.com/papers/68e586b5b6db6435875231ca https://doi.org/10.1158/0008-5472.27028774

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Figure S8 from Targeting the immunoglobulin IGSF9 enhances anti-tumor T cell activity and sensitivity to anti-PD-1 immunotherapy2024
2Figure S5 from Targeting the immunoglobulin IGSF9 enhances anti-tumor T cell activity and sensitivity to anti-PD-1 immunotherapy2024
3Figure S1 from Targeting the immunoglobulin IGSF9 enhances anti-tumor T cell activity and sensitivity to anti-PD-1 immunotherapy2024
4Figure S2 from Targeting the immunoglobulin IGSF9 enhances anti-tumor T cell activity and sensitivity to anti-PD-1 immunotherapy2024
5Figure S6 from Targeting the immunoglobulin IGSF9 enhances anti-tumor T cell activity and sensitivity to anti-PD-1 immunotherapy2024